# Vyriad

Source: https://onco.cc/companies/vyriad/  
OnCo record `vyriad` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vyriad is a United States-based biotechnology company running 2 late-stage cancer trials in melanoma, head and neck squamous cell carcinoma and colorectal cancer.

## Summary

Vyriad, based in Rochester, the United States, is a biotechnology company. Vyriad engineers targeted viral platforms for genetic therapies, developing in vivo gene therapies, genome editing and oncolytic virotherapies delivered through engineered virus vectors, including VSV and measles virus platforms. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in melanoma, head and neck squamous cell carcinoma, colorectal cancer, non-small-cell lung cancer and neuroendocrine tumours. The largest, NCT04291105 (Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients), plans to enrol 87 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Vyriad, Inc.
- Tags: ctgov-sponsor
- HQ: Rochester
- Type: biotech
- Website: https://www.vyriad.com

## Sources

- Official website: https://www.vyriad.com
- ClinicalTrials.gov: trials led by Vyriad: https://clinicaltrials.gov/search?lead=Vyriad%2C%20Inc.

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Melanoma](https://onco.cc/cancers/melanoma/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- trials: [Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors](https://onco.cc/trials/nct03647163/), [Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients](https://onco.cc/trials/nct04291105/)

---
JSON: https://onco.cc/api/v1/entities/vyriad.json